Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03526250 · OUTCOME

Percentage of Patients Experiencing Grade 3 or Higher Adverse Events

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) · Source last updated 2026-04-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
From enrollment to 30 days after the end of treatment, up to 2 years

What was measured

Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.

Analysis population: Three patients did not receive any protocol therapy and are excluded from this analysis.

Groups in this outcome

Treatment (Palbociclib)

Patients receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Palbociclib)20

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Palbociclib)100Not reported100100Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        100
        upper Limit
        100
        value
        100
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    units
    Participants
description
Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treatment (Palbociclib)
param Type
NUMBER
population Description
Three patients did not receive any protocol therapy and are excluded from this analysis.
reporting Status
POSTED
time Frame
From enrollment to 30 days after the end of treatment, up to 2 years
title
Percentage of Patients Experiencing Grade 3 or Higher Adverse Events
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice